RLYBRallybio Corpvs its industry peers
A metric-by-metric comparison of Rallybio Corp against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLYBThis | $85M#2 | 3.4x#1 | 0.9x#2 | 99.3x#4 | 34.9%#2 | 84.5%#1 | -3853.6%#4 | -9.7%#2 | — | — | 184.6%#1 | — |
| PLYX | $93M#1 | — | 8.5x#6 | — | — | 70.4%#2 | — | -82.1%#5 | — | — | — | — |
| EMMA | $84M#3 | — | — | 6.8x#2 | -25.2%#4 | -16.1%#4 | 1.9%#2 | — | — | 4#2 | — | — |
| COYA | $81M#4 | — | 1.9x#3 | 10.2x#3 | 123.6%#1 | -42.6%#6 | -283.9%#3 | -49.0%#3 | — | — | — | — |
| PDSB | $76M#5 | — | — | — | — | 8.3%#3 | — | — | -541.6%#3 | — | — | — |
| CRBP | $76M#6 | — | 0.7x#1 | — | -100.0%#5 | -95.3%#8 | — | -76.8%#4 | -93.1%#2 | — | — | — |
| CING | $74M#7 | — | 3.1x#5 | — | — | -35.6%#5 | — | -95.7%#6 | — | — | — | — |
| LFVN | $73M#8 | 14.7x#2 | 2.2x#4 | 0.4x#1 | -20.1%#3 | -48.3%#7 | 3.3%#1 | 15.1%#1 | 28.2%#1 | 6#1 | — | 3.2%#1 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice